

Q3

ELOS 
MEDTECH

Interim report for the period 1 January to 30 September, 2017

Growth in several market segments in Q3

January-September

- **Net sales** for the first nine months of the financial year increased and amounted to SEK 429.0 M (418.7), corresponding to growth of 2.5%.
- **Operating profit** totalled SEK 36.1 M (39.7).
- **Profit after net financial items** was SEK 20.7 M (32.1). Net financial items were negatively affected by exchange rate differences of SEK -8.4 M (1.1).
- **Profit after tax** was SEK 15.1 M (23.5), corresponding to SEK 2.50 (3.88) per share.
- **Cash flow from operations** was SEK 42.9 M (73.3), and after investments SEK 25.2 M (53.7).

+4.5%

Growth in Q3, value-adjusted 3.0%

+2.5%

Growth in the first nine months of the year, value-adjusted 1.0%

Key figures	July-Sept	July-Sept	Jan-Sept	Jan-Sept	Oct-Sept	Jan-Dec
	2017	2016	2017	2016	2016/17	2016
Net sales, SEK M	132.5	126.7	429.0	418.7	562.3	552.0
Growth, %	4.5	3,7	2.5	14,7	2.0	10,1
EBITDA, SEK M	22.1	25.4	75.5	80.2	92.7	97.3
EBITDA, %	16.7	20.0	17.6	19.2	16.5	17.6
EBIT, SEK M	9.3	11.7	36.1	39.7	39.1	42.7
EBIT, %	7.0	9.2	8.4	9.5	6.9	7.7
Profit after financial items, SEK M	5.2	10.8	20.7	32.1	26.5	37.9
Profit after tax, SEK M	3.0	8.5	15.1	23.5	18.0	26.4
Profit after tax per share, SEK	0.50	1.39	2.50	3.88	2.99	4.37

